Can activity at CTLA-4 be added to PD-1 x VEGF blockade?

Skyscraper-07 fails, while a Poseida-originated Car-T is also scrapped.

The curtain lifts on Veritac-2, rusfertide, and another double plenary for Astra.

Meanwhile, the company plays down the risk of Jaypirca’s CLL approval being rescinded.

The PD-1 x VEGF molecule's latest win comes from Akeso's Harmoni-6 trial.